{"result": "(\"entity\"<|>GLUTAMINA<|>ORGANIZATION<|>Glutamina is a non-essential amino acid that is conditionally essential in certain catabolic states, playing a crucial role in various metabolic processes and energy source for intestinal cells.)\n##\n(\"entity\"<|>METOTREXATO<|>ORGANIZATION<|>Metotrexato is a cytotoxic agent that interacts pharmacokinetically with glutamine, potentially increasing its intratumoral concentrations and effects.)\n##\n(\"entity\"<|>EICH<|>EVENT<|>EICH refers to the early immune response that can be affected by glutamine supplementation, particularly in patients undergoing chemotherapy.)\n##\n(\"entity\"<|>TRASPLANTE DE CÉLULAS HEMATOLÓGICAS<|>EVENT<|>Hematopoietic cell transplantation is a medical procedure where glutamine's effects are studied, showing controversial results regarding its use.)\n##\n(\"relationship\"<|>GLUTAMINA<|>METOTREXATO<|>Glutamina can decrease the renal clearance of metotrexato, leading to higher exposure to the drug<|>7)\n##\n(\"relationship\"<|>GLUTAMINA<|>EICH<|>Glutamina has been studied for its effects on EICH, particularly in relation to mucositis and chemotherapy<|>5)\n##\n(\"relationship\"<|>GLUTAMINA<|>TRASPLANTE DE CÉLULAS HEMATOLÓGICAS<|>Glutamina is used in the context of hematopoietic cell transplantation, with mixed evidence regarding its benefits<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: esquelético. Es un aminoácido no esencial, que es considerado como «condicionalmente» esencial en ciertos estados catabólicos, ya que disminuye en enfermedades agudas y graves (sepsis, traumatismos, quemaduras) y sus concentraciones plasmáticas bajas se correlacionan inversamente con el pronóstico56. Es un sustrato fundamental en muchos procesos metabólicos, como son la transferencia interórganos de nitrógeno, el transporte de carbono, la síntesis de ácidos nucleicos y proteínas, la gluconeogénesis y la homeostasis del equilibrio ácido-base. Asimismo, constituye una importante fuente de energía para las células de la mucosa intestinal, y otras células con una alta tasa de replicación como son las células del sistema inmune57. Estudios en ratas demuestran que la suplementación con glutamina en estados catabólicos resulta beneficiosa58, 59. Sin embargo, Alpers60 refiere que estos resultados pueden no ser extrapolables a los humanos. Durante la enfermedad crítica la administración intravenosa de aminoácidos (glutamina para prevenir su pérdida desde el músculo, alanina para disminuir la transaminación del glutamato y valina para aportar nitrógeno que favorezca la producción de glutamina desde el α-ketoglutarato) aumenta los niveles plasmáticos de glutamina pero no sus niveles musculares.\n\nLa glutamina tiene interacciones farmacocinéticas con agentes citotóxicos como el metotrexato. Puede disminuir el aclaramiento renal de este fármaco, exponiendo al huésped a dosis superiores a las inicialmente pautadas. Además, aumenta las concentraciones intratumorales del metotrexato, lo cual potenciaría sus efectos tumoricidas frente a la administración del fármaco de forma aislada.\n\nLa evidencia existente en relación con su uso en pacientes con trasplante de células hematológicas es controvertida61. Se ha empleado en dos modalidades: oral y parenteral. En la última revisión sistémica y metanálisis realizado en adultos62 se objetivaron resultados dispares entre su administración oral y su administración intravenosa. Este metanálisis incluyó 17 estudios aleatorizados con alto grado de heterogeneidad entre ellos en términos demográficos y del esquema terapéutico de glutamina empleado (tabla 7).\n\n#### 8.3.1. Glutamina por vía oral\n\nEn los distintos estudios la glutamina se ha administrado disuelta en agua o en otros líquidos, manteniéndola inicialmente en la boca a modo de enjuague.63 La administración oral de glutamina en pacientes con y sin mucositis causa un aumento en los niveles plasmáticos de glutamina64, 65, lo cual sugiere que la absorción es adecuada y que pueden producirse efectos sistémicos66, 67. La glutamina oral no ha demostrado ningún efecto sobre la mortalidad, las infecciones o el tiempo de recuperación de la cifra de neutrófilos62. Sí se ha objetivado una reducción de la mucositis (disminución de su duración, severidad y del tiempo que se precisa tratamiento con opiáceos) y de la EICH (posiblemente debido a que la mucositis en un factor de riesgo para la EICH68, 69). Este efecto es más potente si se administra antes del día 0, lo cual sugiere que su función primordial consistiría en reducir el daño que la quimioterapia ejerce sobre la mucosa intestinal, actuando a través de la vía del glutatión62. Existe también una tendencia hacia una disminución de duración de la estancia media hospitalaria y de la duración del soporte nutricional con NP.\n\n#### 8.3.2. Glutamina en nutrición parenteral\n\nLa glutamina intravenosa produce menor atrofia de la mucosa intestinal y mejoría de su función, lo cual sugiere que, a pesar de administrarse por vía intravenosa, este aminoácido ejercería efectos locales sobre el intestino70. No se ha demostrado efecto, sin embargo, en los siguientes puntos registrados en el día +100: mortalidad, mucositis, EICH y recuperación de la cifra de plaquetas. Sí parece disminuir el número de infecciones clínicas (riesgo relativo 0,75) y de cultivos microbiológicos positivos, al igual que ocurre en los pacientes críticos71. Basándose en un estudio62 realizado en pacientes sometidos a trasplantes autólogos, la glutamina intravenosa parece aumentar la mortalidad a largo plazo, fundamentalmente por relacionarse con un aumento del tiempo de recuperación de la cifra de neutrófilos. Se han propuesto varios motivos para explicar este efecto sobre la recuperación de los neutrófilos: el efecto conocido como «alimentar al tumor»72; la disminución del efecto que los rad\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}